Altisource Announces Fourth Quarter and Full Year 2023 Financial Results
LUXEMBOURG, March 07, 2024 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider […]
TSX News -
KP Tissue Releases Fourth Quarter and Full Year 2023 Financial Results
MISSISSAUGA, Ontario, March 07, 2024 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2023 and full […]
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PDUFA target action date is March 16, 2024, for the Company’s sNDA. If approved, the Company is prepared for launch […]
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic […]
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first […]
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) […]
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of […]
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
Q4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, […]
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD […]
AirSculpt Technologies Announces Participation at BofA Securities Consumer and Retail Conference
MIAMI BEACH, Fla., March 07, 2024 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of […]
